Crystal structure of rhodopsin bound to arrestin by femtosecond X-ray laser. by Kang, Yanyong et al.
UCLA
UCLA Previously Published Works
Title
Crystal structure of rhodopsin bound to arrestin by femtosecond X-ray laser.
Permalink
https://escholarship.org/uc/item/5gj723w0
Journal
Nature, 523(7562)
ISSN
0028-0836
Authors
Kang, Yanyong
Zhou, X Edward
Gao, Xiang
et al.
Publication Date
2015-07-22
DOI
10.1038/nature14656
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Crystal structure of rhodopsin bound to arrestin by femtosecond 
X-ray laser
A full list of authors and affiliations appears at the end of the article.
Abstract
G protein-coupled receptors (GPCRs) signal primarily through G proteins or arrestins. Arrestin 
binding to GPCRs blocks G protein interaction and redirects signaling to numerous G protein-
independent pathways. Here we report the crystal structure of a constitutively active form of 
human rhodopsin bound to a pre-activated form of the mouse visual arrestin, determined by serial 
femtosecond X-ray laser crystallography. Together with extensive biochemical and mutagenesis 
data, the structure reveals an overall architecture of the rhodopsin-arrestin assembly, in which 
rhodopsin uses distinct structural elements, including TM7 and Helix 8 to recruit arrestin. 
Correspondingly, arrestin adopts the pre-activated conformation, with a ~20° rotation between the 
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N- and C- domains, which opens up a cleft in arrestin to accommodate a short helix formed by the 
second intracellular loop of rhodopsin. This structure provides a basis for understanding GPCR-
mediated arrestin-biased signaling and demonstrates the power of X-ray lasers for advancing the 
frontiers of structural biology.
G protein-coupled receptors (GPCRs) comprise the largest family of cell surface receptors, 
which signal primarily via G proteins or arrestins1,2. Upon activation, GPCRs recruit 
heterotrimeric G proteins and subsequently G protein-coupled receptor kinases (GRKs), 
which phosphorylate GPCRs to allow the high affinity binding to arrestin3. Arrestin binding 
to the receptors blocks their interactions with G proteins and leads to the receptor’s 
desensitization4. The binding of arrestins to GPCRs also initiates numerous cellular 
signaling pathways that are independent of G proteins. Arrestin-mediated signaling is 
therefore a central component of the GPCR functional network.
GPCRs are targets of one-third of the current clinically used drugs. Recent studies have 
demonstrated that G-protein and arrestin pathways are distinct and can be pharmacologically 
modulated independently using biased GPCR ligands, which selectively modulate either G-
protein or arrestin pathways5. Biased GPCR ligands are often preferred over unbiased 
agonists and antagonists, as they selectively direct the receptor to a subset of partners and 
can deliver therapeutic benefits with fewer undesirable side effects. Research toward biased 
ligands has become a new trend for GPCR-targeting therapeutics6.
The molecular mechanisms of GPCR signaling have been unraveled by recent 
breakthroughs in GPCR structural biology7–10. In the antagonist-bound state, GPCRs 
assume a closed conformation with the cytoplasmic ends of the transmembrane (TM) helices 
packed closely with each other7,9, thus blocking the interactions with G proteins or arrestins. 
In contrast, agonist binding promotes conformational changes in GPCRs, including a 
dramatic movement within the cytoplasmic side of the TM domain8,11–14, thus allowing 
activated receptors to recruit G proteins or arrestins to mediate downstream signaling. 
However, arrestin coupling to GPCRs may require a conformation of the receptor different 
from that required for coupling with G proteins14,15.
Rhodopsin is a prototypical GPCR responsible for light perception7. Along with β2AR, 
rhodopsin has served as a model system for studying GPCR signaling16. Figure 1a shows 
rhodopsin binding to G protein and arrestin. Light induces isomerization of 11-cis-retinal to 
all-trans-retinal (ATR), which activates rhodopsin and promotes its interactions with G 
protein17,18. Light-activated rhodopsin is then phosphorylated by rhodopsin kinase (GRK1), 
leading to high affinity recruitment of arrestin that terminates the G protein signaling. 
Activation of rhodopsin can also be achieved through mutations, including the E1133.28Q /
M2576.40Y mutation, which yields a constitutively active rhodopsin19 (Superscripts in 
residues refer to the Ballesteros-Weinstein numbering20). The crystal structure of bovine 
rhodopsin has been determined in the inactive, resting state7, the ligand-free state21,22, and 
the ligand-activated state in complex with a G protein peptide23. Arrestin structures have 
also been determined in the inactive24,25 and pre-activated form1,2. Recent electron 
microscopy (EM) analysis has revealed the assembly and conformational dynamics of the 
β2AR-β-arrestin complex26. Here we report the crystal structure of an active form of human 
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rhodopsin bound to a pre-activated mouse visual arrestin, determined by serial femtosecond 
crystallography (SFX). The structure has been confirmed by EM, double electron-electron 
resonance (DEER), hydrogen-deuterium exchange mass spectrometry (HDX), cell-based 
rhodopsin-arrestin interaction assays, and site-specific disulfide cross-linking experiments. 
Our study provides a molecular basis for understanding GPCR-mediated arrestin-biased 
signaling.
Characterization and crystallization of the rhodopsin-arrestin complex
To characterize the rhodopsin-arrestin interaction, we expressed and purified E1133.28Q and 
E1133.28Q/ M2576.40Y mutant receptors (Extended Data Fig. 1a). These mutations were 
introduced in the context of the N2NtermC/N282ECL3C mutant that is known to create a 
disulfide bond that increases rhodopsin stability without affecting its activity27–29. The 
N2NtermC/N282ECL3C mutant is referred to as our wild type (WT) control. To determine the 
interaction between rhodopsin and arrestin, we developed a bead binding pull-down assay. 
In this assay, rhodopsin expressed as a fusion with a maltose-binding protein (MBP) at its 
N-terminus was bound to amylose beads, which were then used to pull down in vitro 
translated arrestin labeled with 35S. Figure 1b shows that WT arrestin has weak background 
binding to WT rhodopsin. The E1133.28Q mutation increased WT arrestin binding by 2–3 
fold, and the E1133.28Q /M2576.40Y mutation further increased the binding of WT arrestin 
in the presence of all-trans-retinal (4–8 fold). In contrast to the relatively weak binding of 
WT arrestin, the binding of 3A_arrestin, a pre-activated form of arrestin that obviates the 
need for receptor phosphorylation for high affinity binding through three alanine mutations 
in L374, V375, and F376 in the C-terminal tail of arrestin, is much stronger. In the absence 
of all-trans-retinal, we observed a nearly 30-fold increase of 3A_arrestin binding to the 
E1133.28Q /M2576.40Y receptor. All-trans-retinal further increased 3A_arrestin binding to 
the E1133.28Q /M2576.40Y receptor by ~60-fold above the binding of WT arrestin to WT 
rhodopsin (Fig. 1b and Extended Data Fig. 1b).
We also measured rhodopsin-arrestin interactions using AlphaScreen assays (Extended Data 
Fig. 1c) with His8-tagged rhodopsin and biotin-tagged arrestin. WT arrestin interacted 
weakly with the E1133.28Q /M2576.40Y rhodopsin, regardless of the presence of all-trans-
retinal (Fig. 1c). As a positive control, the GαCT peptide, a high affinity peptide variant of 
the C-terminus of G-transducin (Gt)30, readily interacted with the E1133.28Q /M2576.40Y 
receptor in the absence of all-trans-retinal, and addition of all-trans-retinal slightly increased 
this interaction (Extended Data Fig. 1d). Quantitative competition using unlabeled 
3A_arrestin or GαCT with the E1133.28Q /M2576.40Y receptors revealed an IC50 value of 
15 nM and 700 nM for the binding of 3A_arrestin and the GαCT peptide, respectively (Fig. 
1d and Extended Data Fig. 1d). The strength of the interaction between the E1133.28Q /
M2576.40Y rhodopsin and the 3A_arrestin is in a similar range as the estimated Kd value of 
30–80 nM for the binding of arrestin to the fully activated phosphorylated rhodopsin31.
Mixing individually purified proteins did not yield a stable 1:1 complex, nor did it lead to 
crystallization. Extensive biochemical data support a 1:1 stoichiometry in the rhodopsin-
arrestin complex32,33. Therefore, we engineered a fusion protein in which 3A_arrestin is 
linked by a 15-residue linker to the C-terminus of E1133.28Q /M2576.40Y rhodopsin. We 
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expressed and purified the rhodopsin-arrestin fusion protein, as well as a T4 lysozyme 
(T4L)-rhodopsin-arrestin fusion, in which a T4L is fused to the N-terminus of rhodopsin to 
increase the soluble surface for crystallization (Extended Data Fig. 2a). The T4L-rhodopsin-
arrestin fusion protein is monomeric and relatively stable with a Tm of 59 °C (Extended 
Data Fig. 2b–c). Negative stain EM images revealed that E1133.28Q /M2576.40Y rhodopsin 
and 3A_arrestin form a stable complex with arrestin bound to the cytoplasmic side of 
rhodopsin (Fig. 1e). The T4L-rhodopsin-arrestin fusion protein formed crystals with sizes in 
the range of 5 to 15 μm under various lipid cubic phase (LCP) crystallization conditions 
(Extended Data Fig. 2d–e). Despite extensive optimization, the crystals diffracted only to 6–
8 Å at synchrotron sources (Extended Data Fig. 2f). We thus turned our attention to the 
emerging method of SFX34 with an LCP injector (LCP-SFX)35,36.
Structure determination by serial femtosecond crystallography
Because of the small size of crystals, we hypothesized that diffraction by X-ray free electron 
laser (XFEL) would improve data quality given the advantages of intense and very short 
XFEL pulses for micrometer-size crystals. In the LCP-SFX method, a stream of gel-like 
LCP with fully hydrated microcrystals runs continuously in vacuum across the 1.5 μm-
diameter XFEL beam, which delivers 120 X-ray pulses per second with less than 50 fs pulse 
duration and sufficient intensity to capture crystal diffraction patterns with a single pulse. 
Within ~12 h of run time, we collected over 5 million detector frames, of which 22,262 had 
more than 40 diffraction spots as determined by the Cheetah hit-finding software37. 
Diffraction patterns from 18,874 crystals could be indexed and integrated using CrystFEL38. 
The data were processed according to the apparent point group of 4/mmm with a large unit 
cell (a=b=109.2 Å and c=452.6 Å). The diffraction was anisotropic with resolution limits of 
3.8 Å and 3.3 Å along the a*/b* and c* axes, respectively (Supplementary Table 1a and Fig. 
5).
The crystals appeared to be pseudo-merohedrally twinned in P212121 (Supplementary Table 
2) and the structure was solved by molecular replacement using known structures of active 
rhodopsin39 and pre-activated arrestin1 (Details in methods). The structure contains four 
rhodopsins (residues 1–326), four arrestins (residues 12–361 with a small missing loop of 
residues 340–342), and three T4Ls (residues 2–161 in complexes A and D; residues 2–12 
and 58–162 in complex C; no T4L was modeled in Complex B due to poor density) (Figure 
2). The final structure was refined to Rwork and Rfree of 25.2% and 29.3%, respectively, with 
excellent geometry (Supplementary Table 1b). The overall arrangement of the T4L-
rhodopsin-arrestin complex is well supported by the electron density maps (Extended Data 
Fig. 3), including a 3000 K simulated annealing omit map. Because of the twinned nature of 
the datasets, we performed extensive structure-validation experiments, including DEER, 
HDX, cell-based rhodopsin-arrestin interaction assays and site-specific disulfide cross-
linking. Below we describe the rhodopsin-arrestin structure and the results of validation 
experiments.
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Overall structure of the rhodopsin-arrestin complex
The most striking feature of the rhodopsin–arrestin complex is the asymmetric binding of 
arrestin to rhodopsin (Fig. 2) and this asymmetric arrangement is similar in all four 
complexes in the asymmetric unit, providing an independent confirmation of the rhodopsin-
arrestin complex assembly (Extended Data Fig. 4). Figure 2a shows one rhodopsin-arrestin 
complex in four 90° orientations. From the intracellular (IC) view, rhodopsin and arrestin 
have similar heights, but the width of arrestin is nearly three times that of rhodopsin. Figure 
2b shows the rhodopsin–arrestin complex in a transparent surface, whose overall 
arrangement of the domains can be fit into the EM images (Fig. 1e). Figure 2c shows the 
layered or Type I packing of the complex in the crystal lattice with alternating hydrophilic 
and hydrophobic layers comprising arrestin, T4L, and rhodopsin, respectively (Fig. 2c). This 
arrangement allows the complex to form extensive packing interactions that involve all 
soluble portions of the proteins, with the arrestin being the central mediator for packing with 
T4L, rhodopsin, and arrestin from neighboring symmetry related molecules.
To validate the assembly of the rhodopsin-arrestin complex, we used DEER to determine 
intermolecular distances within the complex40. The DEER distances from residue Y742.41 of 
rhodopsin to three arrestin residues (T61, V140, and T241) measured in a non-fused 
rhodopsin-arrestin complex were 28 Å, 23 Å and 33 Å, closely matching the distances of 28 
Å, 22 Å, and 34 Å, respectively, as observed in the crystal structure (Fig. 3). The 
intramolecular distances in the active arrestin bound to light-activated phosphorylated 
rhodopsin have also been studied extensively by DEER41, and all of them match 
exceedingly well with the crystal structure (Supplementary Table 3). Together, these data 
support that the complex formed by fusion proteins closely resembles the physiologically 
relevant complex formed by individual proteins.
The rhodopsin-arrestin interface
The four rhodopsin-arrestin complexes in the asymmetric unit adopt nearly identical 
interfaces (Extended Data Fig. 4a), which are stabilized by intermolecular interactions as 
summarized in Supplementary Table 4. The total surface area buried in the interface is 1350 
Å2, which is substantially smaller than the area (2576 Å2) buried in the β2AR-Gs complex8. 
Unlike the continuous interface observed in the β2AR-Gs complex, the rhodopsin-arrestin 
complex has four distinct arrestin interface patches (Fig. 4a–b and Extended Data Fig. 4b). 
The first arrestin interface patch consists of the finger loop (residues Q70 to L78), which 
adopts a short α-helix and forms extensive interactions with the C-terminus of TM7 and the 
N-terminus of Helix 8, as well as the loop residues (ICL1) of rhodopsin. Interactions of 
arrestin with TM7 of rhodopsin are of particular interest because conformational changes in 
TM7 have been implicated in arrestin-biased signaling14,15. Moreover, the close interactions 
between rhodopsin’s Helix 8 and arrestin have been shown to be essential for high-affinity 
binding of arrestin to the activated rhodopsin42. The second arrestin interface patch is 
formed by the middle loop (residue V140 region) and the lariat loop (residue Y251 region) 
that interact with the ICL2 of rhodopsin, and the arrestin back loop (R319 and T320) that 
interacts with the C-terminus of TM5. The middle and lariat loops are close to each other in 
the inactive arrestin, but move apart upon its activation to form a cleft that accommodates 
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the ICL2 of rhodopsin, which adopts a short helix (Fig. 4a–b). The positions of the finger 
loop and the lariat loop are supported by a composite omit 2Fo-Fc electron density map 
(Extended Data Fig. 3d). The third arrestin interface patch is the β-strand (residues 79–86), 
which follows the finger loop and interacts with residues from TM5, TM6 and ICL3 of 
rhodopsin. The fourth arrestin putative interface patch is mostly between its N-terminal β-
strand (residues 11–19) and the C-terminal tail of rhodopsin, which was not visible in the 
electron density map due to the apparent flexibility of this region but was computationally 
modeled based on HDX and disulfide cross-linking data described below (Extended Data 
Fig. 5). Consistent with the crystal structure, these arrestin elements have been implicated in 
various aspects of arrestin activation and receptor binding43,44.
To further characterize the rhodopsin-arrestin interfaces, we performed three additional sets 
of validation experiments. The first was HDX, which probes the dynamics and stability of 
protein complexes45. Compared with free arrestin, the rhodopsin-bound arrestin has several 
regions that are protected from exchange, including the finger loop and the N-terminal β-
sheets, consistent with their location in the rhodopsin-binding interface (Fig. 4c–d, and 
Extended Data Fig. 6a). The hydrogen to deuterium exchange rate of arrestin in the complex 
is lower than that for free arrestin across the whole protein, indicating that arrestin is 
stabilized by complex formation, consistent with the results of previous HDX experiments46 
and thermal stability assays, which revealed that the melting temperature of free arrestin is 
six degrees lower than that of the complex (53 ° C vs. 59 ° C, Extended Data Fig. 6b).
The second set consisted of Tango assays47, which have been used for probing GPCR-
arrestin interactions (Extended Data Fig. 7a). WT rhodopsin and WT arrestin had a very low 
basal interaction and all-trans-retinal increased the binding by ~3-fold. In contrast, 
E1133.28Q /M2576.40Y rhodopsin showed a high level of interaction with the pre-activated 
3A_arrestin, and addition of all-trans-retinal further increased the binding signal by ~5-fold. 
Mutations in finger loop (D74, M76, G77, and L78), middle loop (Q134 and D139), and 
lariat loop (L250 and Y251) decreased rhodopsin-arrestin binding (Extended Data Fig. 7b). 
Correspondingly, mutations in rhodopsin residues involved in arrestin binding also 
weakened the interaction (Extended Data Fig. 7c), consistent with the complex crystal 
structure.
The third set consisted of site-specific disulfide cross-linking experiments, which have been 
used to validate structures based on the geometry requirements for disulfide bond formation 
(Cα –Cα distances of 5–9 Å and appropriate side-chain orientations). We engineered 
cysteine pairs at the binding interface of arrestin and rhodopsin, which were tagged with 
FLAG and HA, respectively. Over 314 co-expression combinations were tested and 
monitored by SDS-PAGE followed by Western blotting (Extended Data Fig. 8). The results 
are summarized in Supplementary Table 5. Every interface residue in arrestin was included 
in the study and the results closely agree with the crystal structure. For example, the 
distances from the Cα atom of the finger loop residue G77 of arrestin to the Cα atoms of 
N3107.57, K3118.48 and Q3128.49 in rhodopsin fit the requirement for disulfide bond 
formation (Fig. 5a). G77C cross linked efficiently with N3107.57C and Q3128.49C, but not 
with K3118.48 C because the Cβ of K3118.48 points away from G77 (Fig. 5a). Neither did 
G77C show cross-linking with a large set of other rhodopsin residues, indicating the high 
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specificity of the cross-linking experiments (Extended Data Fig. 8c and Supplementary 
Table 5). In contrast, several other mutants in the finger loop region (D74C, M76C, and 
L78C) readily cross-linked with Q3128.49C from Helix 8 (Fig. 5a). The cross-linking results 
of these four finger loop residues not only matched the crystal structure, but also agreed well 
with the results from the Tango assays (Extended Data Fig. 7b). In addition, mutants of three 
N-terminal finger loop residues (Q70C, E71C, and D72C) were cross-linked to mutants in 
rhodopsin ICL1 T70ICL1C and K67ICL1C, respectively (Extended Data Fig. 7d).
We also observed cross-linking of the arrestin middle loop (D139) with rhodopsin ICL2 
(G149ICL2) (Fig. 5b); of the arrestin lariat loop (Y251) with rhodopsin TM5 (T2295.64 and 
A2335.68) (Fig. 5c); of the arrestin β-strand (residues 79–86) that follows the finger loop 
with rhodopsin TM5, TM6, and ICL3 (Fig. 5d). Additional cross-linking was observed in 
two back-loop residues R319C and T320C of arrestin with Q237ICL3C of TM5 in rhodopsin 
(Extended Data Fig. 8e). Furthermore, extensive crosslinking of the arrestin N-terminus with 
the C-terminal tail of rhodopsin was detected, including R19 of arrestin with S334Cterm of 
rhodopsin (Fig. 5e), K16 of arrestin with S338Cterm and K339Cterm of rhodopsin, and V11 
and S10 of arrestin with the final eight residues of rhodopsin (Supplementary Table 5). 
Together, these cross-linking experiments further validated the interface assembly of the 
rhodopsin-arrestin complex.
Possible structural mechanisms for biased signaling: G protein vs. arrestin
The rhodopsin-arrestin complex represents the first crystal structure of a GPCR bound to 
arrestin and provides an opportunity to examine the mechanism of arrestin-biased signaling. 
Although a crystal structure of G protein-bound rhodopsin is not available, a number of 
rhodopsin structures bound to GαCT have been determined11,23,39 and reveal that the 
arrangement of TM helices in light-activated rhodopsin is similar to that in the G protein-
bound β2AR complex, with the exception of TM6, whose outward movement in β2AR is 
much more pronounced upon binding to G protein8. The arrestin-bound rhodopsin has its 
intracellular end of TM6 moved outward by ~10 Å relative to its inactive structure (Fig. 6a–
b and Extended Data Fig. 9). This is in contrast to the 14 Å outward movement of TM6 
reported in the G protein-bound β2AR complex8. Compared to the GαCT-bound 
rhodopsin11, arrestin-bound rhodopsin has additional conformational differences in TM1, 
TM4, TM5, and TM7 (Fig. 6c–d and Extended Data Fig. 9), and these unique structural 
features may constitute essential elements for arrestin-biased signaling.
The molecular assembly observed in the rhodopsin-arrestin complex also provides a general 
model for arrestin recruitment by phosphorylated rhodopsin-like class A GPCRs. In the 
computational model of the full complex, the highly cationic N-terminal domain of arrestin 
is paired with the C-terminal tail of rhodopsin (Extended Data Fig. 10). Based on the 
extensive disulfide crosslinking data and computation modeling, phosphorylated S334, S338 
and S343 can form tight ionic interactions with three positively charged pockets at the N-
terminus of arrestin (Extended Data Figure 11a–d). These results support a model of arrestin 
activation by phosphorylated rhodopsin through the C-tail exchange mechanism (Fig. 6e)2. 
The displacement of the arrestin C-terminus by the phosphorylated rhodopsin C-tail 
destabilizes the polar core of arrestin48, thus allowing for a 20° rotation of the N- and C- 
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domains of arrestin that opens a cleft between the middle and lariat loops into which the 
ICL2 helix of rhodopsin can fit. The ionic interaction between rhodopsin and arrestin is 
consistent with the fact that it is highly salt sensitive in our AlphaScreen assay (Extended 
Data Fig. 11e), in agreement with the salt sensitive binding of phosphorylated rhodopsin to 
arrestin43,48. Importantly, the cytoplasmic face of the rhodopsin TM bundle is highly 
positively charged whereas the finger loop (residues 70–78) contains three conserved 
negatively charged residues (E71, D72, and D74) (Extended Data Fig. 10). Thus, the 
interaction of arrestin with the rhodopsin TM bundle is mediated not only by shape but also 
by charge complementarity. Arrestins are highly conserved with only four subtypes in 
vertebrates. In contrast, there are hundreds of GPCRs, with cytoplasmic interfaces that are 
largely non-conserved. However, the positive charge property is widely presented on the 
cytoplasmic side of a number of GPCR structures (Extended Data Fig. 12). Electrostatic 
interactions between arrestins and GPCRs may represent an adaptive mechanism for 
arrestins to pair promiscuously with the large number of GPCRs.
The asymmetric orientation of the bound arrestin with regard to the relative positions of its 
N-C domains in respect to the membrane has important implication in its binding to 
rhodopsin (Fig. 2a–b). Such asymmetric assembly brings the arrestin C-domain toward the 
membrane, with the C-edge either being touched or embedded in the membrane layer 
(Extended Data Figure 13). The C-edge is comprised of conserved hydrophobic residues 
(F197, F198, M199, F339, and L343). It has been puzzling why single alanine mutations at 
these residues would affect arrestin binding to rhodopsin given how far away they are from 
the receptor43. The close proximity of these hydrophobic residues to the lipid membrane 
may provide an explanation for the effects of their mutations on binding to rhodopsin. 
GPCR signaling regulator proteins are normally membrane associated through lipid 
modifications, as is the case for GRK1 and the G-protein subunits Gα and Gβγ. Yet, there is 
no known lipid modification for any of the arrestins. We speculate that the conserved 
hydrophobic patch at the C-edge of arrestin may function as a lipid-interacting module that 
helps to stabilize its interaction with the receptor. Furthermore, one primary function of 
arrestin is to mediate endocytosis of ligand-activated GPCRs and the highly asymmetric 
nature of the arrestin assembly may facilitate the membrane curvature for subsequent 
endocytotic processes. Alternatively, the remote C-edge could serve as the binding site of 
the second rhodopsin, which has been proposed to form dimers in the rod outer-segment disc 
membrane49.
LCP-SFX is a new technology that has been used to determine several crystal 
structures35,36,50. Rhodopsin-arrestin is a challenging membrane protein complex and 
obtaining a structure of this complex at a sufficiently high resolution was an intractable task 
using existing methods that include synchrotron-based crystallography and cryo-EM26. The 
rhodopsin-arrestin complex structure reported here demonstrates the utility of the X-ray 
lasers when combined with SFX and an LCP crystal delivery system35. The SFX method is 
relatively new and under continuous development. Given its success in solving the 
rhodopsin-arrestin structure, we expect that X-ray lasers, with further method development, 
will continue to provide breakthrough insights into biology and chemistry.
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Methods
Protein Preparation
We used human rhodopsin and mouse visual arrestin-1 in this study. The T4L-rhodopsin-
arrestin fusion protein was expressed using a tetracycline-inducible expression cassette 
encoding a fusion protein with His8-MBP-MBP followed by a 3C protease cleavage site at 
the N-terminus of the T4L-rhodopsin-arrestin. In this engineered construct, we have fused a 
cysteine-free T4L (residues 2–161 with C54T and C97A) to the N terminus of a rhodopsin 
that contains four mutations: N2NtermC and N282ECL3C to form a disulfide bond, and 
E1133.28Q and M2576.40Y for constitutive receptor activity. The C terminus of rhodopsin 
was fused to 3A_arrestin (L374A, V375A, F376A, residues 10–392) with a 15 amino acid 
linker (AAAGSAGSAGSAGSA).
The fusion protein constructs were expressed in HEK293S cells (Invitrogen) transiently 
transfected using Lipofectamine 2000 (Invitrogen). Cells were transfected at a density of 
2×106 cells/ml at a 100 ml scale in SFM4TransFx-293 (HyClone). Six hours post 
transfection, cells were diluted ten-fold with CDM4HEK293 medium (HyClone). When the 
cell density reached approximately 4×106 cells/ml, protein expression was induced by the 
addition of doxycycline to a final concentration of 1 μg/ml. After 24 h induction, cells were 
harvested, resuspended in hypotonic buffer (20 mM HEPES-Na, pH 7.5, 10 mM NaCl, 10 
mM MgCl2) supplemented with EDTA-free protease inhibitor cocktail (Roche), followed by 
Dounce homogenization. The lysate was centrifuged at 45,000 rpm at 4 °C for 1 h. Then 
membranes were solubilized in 20 mM Tris-HCl, pH 7.4, 100 mM NaCl, 10% glycerol, 
0.5% (w/v) n-dodecyl-β-D-maltopyranoside (DDM, Anatrace), 0.1% (w/v) cholesteryl 
hemisuccinate (CHS, Anatrace), and protease inhibitor cocktail for two hours at 4 °C. The 
supernatant was isolated by centrifugation at 45,000 rpm for one hour, and incubated with 
amylose beads (New England Biolabs) at 4 °C overnight. Typically 10 ml of resin were used 
for supernatant from one liter of the original cell culture. The resin was washed with 200 ml 
of washing buffer (10 mM Tris-HCl, pH 7.4, 100 mM NaCl, 0.005% (w/v) lauryl maltose 
neopentyl glycol (MNG-3, Anatrace), 0.001% (w/v) CHS) and the protein was eluted with 
washing buffer containing 10 mM maltose. The eluted fusion protein was concentrated to 
40–50 mg per 1 ml and the His8-MBP-MBP tag was cleaved by overnight incubation with 
3C protease at 4 °C. The cleaved His8-MBP-MBP tag was removed by incubating with 300 
μl Ni2+-NTA beads (Qiagen) for three hours at 4 °C. The purified T4L-rhodopsin-arrestin 
was collected and concentrated to 30 mg/ml for crystallization.
WT rhodopsin and rhodopsin mutants E1133.28Q and E1133.28Q /M2576.40Y used for MBP 
pull-down and AlphaScreen assays were expressed from the same vector with His8-MBP 
tag at the N-terminus. Protein expression and purification were similar as for the rhodopsin-
arrestin fusion protein used for crystallization, with the difference that proteins were not 
eluted, but remained bound to beads.
To generate biotinylated proteins for the AlphaScreen assays, WT and 3A_arrestin (residues 
10–392) open reading frames were cloned with N-terminal avitag-MBP tag into the first 
expression cassette of a modified pET-Duet expression vector (Novagen), and the biotin 
ligase gene BirA was cloned into the second cassette. The 14 amino acid avitag contains a 
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single lysine that is efficiently biotinylated in vivo by BirA protein51. BL21 (DE3) cells 
transformed with the expression plasmid were grown in LB broth at 16 °C to an OD600 of 
~1.0 and induced with 0.1 mM IPTG in the presence of 40 μM biotin for 16 h. Cells were 
harvested, resuspended in 50 ml extraction buffer (20 mM Tris-HCl, pH 8.0, 150 mM NaCl, 
and 10% glycerol) per two liters of cells, and passed three times through a French Press with 
pressure set at 1000 Pa. The lysate was centrifuged at 16,000 rpm in a Sorvall SS-34 rotor 
for 30 min, and the supernatant was loaded on a 5 ml amylose HP column (GE Healthcare). 
The column was washed with 100 ml of wash buffer (20 mM Tris-HCl, pH 8.0, 150 mM 
NaCl, and 10% glycerol) and eluted in buffer containing 20 mM Tris-HCl, pH 8.0, 150 mM 
NaCl and 20 mM maltose. The eluted biotin-MBP-arrestin was concentrated and further 
purified by size exclusion chromatography through a HiLoad 16/60 Superdex 200 column 
(GE Healthcare) in 20 mM Tris-HCl, pH 8.0, and 150 mM NaCl. Monomeric protein was 
collected for further assay.
Untagged 3A_arrestin (residues 10–392) was expressed as a His6-SUMO fusion protein 
from the expression vector pSUMO (LifeSensors). The expression and purification of 
untagged arrestin followed the same method as for biotin-MBP-arrestin, except that the 
His6-SUMO tag was cleaved overnight with SUMO protease52 at a protease/protein ratio of 
1:1000 in the cold room.
MBP pull-down assay
Arrestin was cloned into the pCITE-4a vector (Novagen) to allow for transcription from a 
T7 promoter. The TNT Quick Coupled Transcription and Translation kit was used according 
to the manufacturer’s protocol (Promega), to express 35S-methionine-labelled WT arrestin 
and 3A_arrestin (L374A, V376A, and F376A). Radiolabelled WT arrestin and mutant 
arrestin proteins were incubated with His8-MBP-rhodopsin fusion protein immobilized to 50 
μl of maltose agarose bead suspension. Proteins and beads were incubated at 4 °C for one 
hour on a rotating platform in binding buffer containing 20 mM Tris-HCl, pH 7.4, 100 mM 
NaCl and 0.02% DDM/0.004% CHS. The beads were then washed three times with binding 
buffer and resuspended in 400 μl elution buffer (20 mM Tris-HCl, pH 7.4, 100 mM NaCl, 
0.02% DDM/0.004% CHS and 100 mM maltose). The eluates were concentrated and 
incubated at room temperature for 15 minutes with 2 × loading dye. Samples were separated 
on 12% sodium dodecyl sulfate (SDS)-denaturing polyacrylamide gels. Gels were stained 
with Coomassie R-250, dried at 70 °C for 90 minutes, and exposed overnight to a phosphor 
storage screen. Results were visualized on a PhosphorImager (Fuji).
Assays for the interactions between rhodopsin and arrestin or G protein peptide
Interactions between rhodopsin and arrestin were assessed by luminescence-based 
AlphaScreen assay (Perkin Elmer), which our group has used extensively to determine 
ligand-dependent protein-protein interactions of nuclear receptors. The AlphaScreen 
principle is illustrated in Fig. 1c. Briefly, biotinylated arrestin was bound to streptavidin-
coated donor beads and His8-tagged rhodopsin was bound to nickel-chelated acceptor beads. 
The donor and acceptor beads were brought into close proximity by the interactions between 
rhodopsin and arrestin, which were measured in the presence or absence of all-trans-retinal 
(Sigma). When excited by a laser beam of 680 nm, the donor bead emits singlet oxygen that 
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activates thioxene derivatives in the acceptor beads, which releases photons of 520–620 nm 
as the binding signal. The experiments were conducted with 100 nM of rhodopsin and 
arrestin proteins in the presence of 5 μg/ml donor and acceptor beads in a buffer of 50 mM 
MOPS-Na, pH 7.4, 50 mM NaF, 50 mM CHAPS, and 0.1 mg/ml bovine serum albumin. 
The results were based on an average of three experiments with standard errors typically less 
than 10%. GαCT (TGGRVLEDLKSCGLF) and biotinylated GαCT were synthesized by 
Peptide 2.0. For the competition assay, different amounts of untagged arrestin or GαCT 
were added to the reaction to compete with tagged arrestin or GαCT for rhodopsin binding.
Thermal stability assay
The thermal stability assay was performed with the thiol-specific fluorochrome N-[4-(7-
diethylamino-4-methyl-3-coumariny)phenyl]maleimide (CPM) as described previously53. 
Briefly, 10 μg of protein was diluted with dilution buffer (20 mM Tris-HCl, pH 7.5, 200 mM 
NaCl, 0.005% MNG-3/CHS) to 195 μl, while CPM dye stock (4 mg/ml in DMSO) was 
freshly diluted to 0.2 mg/ml in the dark. After 5 min of incubation at room temperature for 
both protein and CPM dye separately, 5 μl of diluted CPM dye was added to the protein 
sample and the protein/dye mix transferred immediately into a sub-micro quartz fluorometer 
cuvette (Starna Cells) and measured in a Cary Eclipse spectrofluorometer (Agilent). Assays 
were performed from 20 °C to 80 °C with a slope of 2 °C increase per minute at an 
excitation wavelength of 387 nm and an emission wavelength of 463 nm. All data were 
processed using GraphPad Prism and fit using the Boltzmann sigmoidal equation to 
determine the melting temperature (Tm) as inflection point of the melting curves.
Crystallization
T4L-rhodopsin-arrestin crystals were grown in lipid cubic phase (LCP)54. Protein solution 
(~30 mg/ml) was mixed with monopalmitolein (9.7 MAG, from Nu-Chek Prep, Inc) 
containing 10% cholesterol at a 1:1 ratio (w/w) using a coupled syringe mixer55 and 50 nl 
boluses of protein-laden LCP were dispensed on 96-well glass sandwich plates (Molecular 
Dimensions or Marienfeld-Superior) and overlaid with 0.8 μl precipitant solutions using a 
Gryphon LCP robot (Art Robbins Instruments) or an NT8-LCP robot (Formulatrix). 
Multiple initial hits were identified by using screens of 30% PEG 400 in combination of 100 
mM or 400 mM salts from the StockOptions Salt kit (Hampton Research)56. Crystals that 
reached full size (around 10–20 μm) within four days at 20 °C were harvested from the 
mesophase and were flash frozen in liquid nitrogen without additional cryoprotectant. 
Crystals used for synchrotron data collection were grown in 0.05 M magnesium acetate, 
0.05 M sodium acetate, pH 5.0 and 28% PEG 400. Crystals for LCP-SFX were prepared in 
100 μL gas-tight Hamilton syringes as described36,57. About 5 μl of protein-laden LCP in 
the presence of 5-fold molar excess of all-trans-retinal was slowly injected into 60 μl mother 
liquid buffer (0.15 M ammonium phosphate, pH 6.4 and 32% PEG 400) using a coupled 
syringe mixing device55. Crystals were grown in several syringes at 20 °C, consolidated and 
transferred into the LCP injector35 for XFEL diffraction data collection. The average crystal 
size was 5–10 μm as determined under a polarized light microscope. The phase diagram for 
9.7 MAG suggests that this MAG is a suitable host lipid for extruding LCP in vacuum at 20 
°C, where evaporative cooling created problems when 9.9 MAG was used as a host LCP 
lipid35.
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Data collection (Synchrotron)
A partial 8.0 Å synchrotron dataset was collected at 100 K using an X-ray beam at the 
wavelength of 1.0 Å at the 21 ID-D beam line of LS-CAT and at 23-ID-D of GM-CAT at 
the Advanced Photon Source at Argonne National Laboratory. A full 7.7 Å dataset was 
collected from a single crystal (~20 microns in size) using 10 μm beam size and 0.1 s 
exposures per 0.1° oscillation with a Pilatus 6M pixel detector at the X10SA beam line at 
the Swiss Light Source. The observed reflections were reduced, merged, and scaled with 
XDS58 with statistics shown in Supplementary Table 1a. The L-test plot of the 7.7 Å dataset 
produced a curve that fits a perfectly twinned crystal.
Data collection (XFEL)
LCP-SFX experiments were carried out at the Coherent X-ray Imaging (CXI) instrument59 
at the Linac Coherent Light Source (LCLS) in the SLAC National Accelerator Laboratory 
(Menlo Park, California, USA). X-ray pulses of 50 fs duration at a wavelength of 1.3 Å (9.5 
keV) were attenuated to ~3% (3·1010 photons/pulse) and focused to ~1.5 μm diameter at the 
interaction point using Kirkpatrick-Baez mirrors60. Rhodopsin-arrestin complex crystals in 
LCP were injected across the XFEL beam using an LCP injector35 with a 50 μm diameter 
nozzle at a flow rate of ~0.2 μL/min. Diffraction patterns were collected at 120 Hz using the 
Cornell-SLAC Pixel Array Detector (CSPAD). Over 5 million data frames were collected 
corresponding to ~12 hours of data acquisition time. Of these frames, ~0.45% images 
contained potential crystal hits as identified using Cheetah61 (more than 40 Bragg peaks of 
1–20 pixels in size and a signal to noise ratio better than 6 after local background 
subtraction). Of the potential crystal hits, 18,874 diffraction patterns could be auto-indexed 
by CrystFEL38 using a combination of MOSFLM62, XDS58 and DirAx63. An integration 
radius of only two pixels was used to avoid overlapping with neighboring peaks due to the 
high spot density resulting from the large unit cell dimensions. Partial reflections from 
different crystals in random orientations were merged using a Monte Carlo integration 
across the crystal rocking curve of each reflection64. The resolution was anisotropic with 
~3.3 Å resolution along the c*-axis and ~3.8 Å resolution along the a*/b* axes. The data 
used for the structure refinement were truncated at 3.8Å/3.8Å/3.3Å using the get_hkl 
program of CrystFEL38 based on the criteria of data correlation coefficient (CC*), which is 
0.87 at the highest resolution shell (Supplementary Table 1a). The use of CC* of 0.5 as 
resolution cutoff has been recently recommended for X-ray diffraction65. The resolution 
cutoff for several published XFEL structures follows this criterion, including the 5HT2B 
GPCR XFEL structure36, which has a CC* of 0.74. The statistics of the final data used in 
structure refinement are shown in Supplementary Table 1b.
Structure determination
The XFEL data were initially merged according to the apparent Laue group of 4/mmm, and 
molecular replacement searches were performed in all possible space groups of 4/m and 4/
mmm. The best structure solution was found in P43. Based on analysis of the Zanuda 
program66, we determined that the most likely space group was P212121 and that the crystals 
were physically twinned. The data were reprocessed with the Laue group of mmm and 
molecular replacement searches were performed in P212121. This space group assignment 
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resulted in the best statistics and map quality out of several possibilities of space groups 
(Supplementary Table 2).
The crystals appeared to be pseudo-merohedrally twinned based on L-test analysis67. 
Despite the challenge of twinned data, the rhodopsin-arrestin complex structure was solved 
by the molecular replacement method implemented in Phaser68 using the models of 
constitutively active rhodopsin, pre-activated arrestin, and T4L (PDB codes: 4A4M39, 
4J2Q1, and 3SN68, respectively). Four molecules of rhodopsin and four molecules of 
arrestin were found sequentially by molecular replacement search, resulting in four very 
similar rhodopsin-arrestin assemblies. Four T4Ls were also found in the aqueous layer with 
its C-terminal residue in a position to form a covalent bond with the first residue of 
rhodopsin, supporting the correct positioning of T4Ls by molecular replacement.
The structure was initially refined against the XFEL data without twin law to an Rfree-factor 
of ~36% and the model maps from the data were of sufficient quality to interpret the overall 
structure of the rhodopsin-arrestin complex (Extended Data Fig. 3). The model then 
underwent iterated cycles of manual building into 2Fo-Fc maps with Coot69 and refinement 
with REFMAC70 and the PHENIX71, where rigid body, individual position, group B-factor, 
and TLS refinements were used along with NCS restraints and twin law (k, h, -l). The 
arrestin residues 70–78 and 165–175, which were not included in the molecular replacement 
model, were manually placed into the density map. These two regions of arrestin became 
visible because they are either engaged in direct interaction with rhodopsin or involved in 
crystal packing. Regions with poor density were removed from the final model, including 
T4L from the B complex and the N-domain of T4L (residues 13–57) from the C complex. 
We did not observe clear electron density for the all-trans retinal, which was thus not 
included in the structure. The structure has been carefully refined to the final state that has 
excellent geometry and refinement statistics (Supplementary Table 1b). Ramachandran plot 
analysis indicates that 100% of the residues are in favorable or allowed regions (no outliers). 
The final structure was validated with MolProbity, which revealed an all-atom-clash score of 
1.47 and MolProbity score of 1.1372.
The real-space correlation coefficients against a 2mFo-DFc map for each chain of the 
structure on a per residue basis using the CCP4 EDSTATS program73 or the MolProbity 
program in Phenix indicated an overall good fit between the structure and the electron 
density map. The density fit correlation in Coot was low with the structure from Phenix 
twinned refinement because the map from the MTZ file with map coefficients produced by 
phenix.refine was not in absolute scale. This problem was overcome by using the 2Fo-Fc 
CNS format map from phenix.refine, which generated a normal correlation in Coot, similar 
to those from EDSTATS and MolProbity. All structural figures were prepared using 
PyMOL74.
Cell-based assays for rhodopsin-arrestin interactions (Tango Assays)
For the cell-based Tango assay47, we generated fusion constructs consisting of rhodopsin 
(1–321), a tobacco etch virus (TEV) protease cleavage site (TEV site), and the 
transcriptional activator tTA (Rho-TEV site-rTA) as well as of arrestin (10–392) and TEV 
protease (Arr-TEV protease). HTL cells were a gift from Dr. Barnea and Dr. Axel (Brown 
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University and Columbia University). 10 ng Rho-TEV site-tTA construct were transfected 
together with 10 ng Arr-TEV protease plasmid and 1 ng of phRG-tk Renilla luciferase 
expression vector into HTL cells using Xtremgene (Roche). One day after transfection, cells 
were induced by vehicle (DMSO) or all-trans-retinal (10 μM) overnight. Cells were 
harvested and lysed in Passive Lysis Buffer (Promega). Luciferase activity was measured 
using the Dual Luciferase Kit (Promega) according to manufacturer’s instructions.
Mutagenesis
Site-directed mutagenesis was carried out using the QuickChange method (Agilent). 
Mutations and all plasmid constructs were confirmed by sequencing prior to protein 
expression, MBP-pull down assay, Tango assay, and AlphaScreen assay.
EM studies of the rhodopsin-arrestin complex
Samples were prepared as previously described75. Briefly, the sample was applied to a 
freshly glow-discharged carbon coated copper grid and allowed to adhere for 10 seconds 
before being reduced to a thin film by blotting. Immediately after blotting 3 μl of a 1% 
solution of uranyl formate was applied to the grid and blotted off directly. This was repeated 
three times. Data were acquired using a Tecnai F20 Twin transmission electron microscope 
operating at 200 kV, with a dose of ~40 e−/Å2 and nominal underfocus ranging from 2 to 3 
μm. Images were automatically collected at a nominal magnification of 62,000 × and pixel 
size of 0.273 nm. All images were recorded with a Tietz F416 4k × 4k pixel CCD camera 
utilizing Leginon data collection software76. Experimental data were processed by the 
Appion software package77, which interfaces with the Leginon database infrastructure. 
~6000 particles were automatically extracted from 54 EM-micrographs78 and the particle 
stack was then aligned and sorted using the XMIPP reference-free maximum likelihood 
alignment79. Several exemplary 2D averages are shown in Figure 1e, which were derived 
from class averages for the complex with or without T4L, computed from ~14000 particles 
selected from 155 EM-micrographs.
In-cell disulfide bond cross-linking
The open reading frames of full-length arrestin with C-terminal FLAG tag and full length 
rhodopsin with C-terminal HA tag were cloned into pcDNA6. Cysteine mutations (41 for 
arrestin and 51 for rhodopsin) were systematically introduced into arrestin and rhodopsin in 
these two DNA vectors. AD293 cells were split one day before transfection at 50,000 cells/
well in a 24-well plate. Cells were grown for one day, then transfected with 100 ng 
rhodopsin constructs (pcDNA6-rho-3HA) plus 100 ng arrestin plasmid (pcDNA6-
Arr-3FLAG) by Lipofectamine 2000 (DNA/Lipofectamine 2000 ratio of 1:2) in each well. 
Cells were grown for 2 days after transfection, and were then treated at room temperature 
with H2O2, which was freshly diluted in the cell culture medium to a final concentration of 1 
mM. After 5 min treatment with H2O2, the medium was aspirated and 100 μl of CelLytic M 
(Sigma C2978) were added to each well and the plate was shaken for 10 min at room 
temperature. Cell lysates were transferred to 1.5 ml tubes and spun at 16,000 x g at 4 °C for 
5 min. The supernatants (10 μl) were mixed with an equal volume of 2×SDS loading buffer 
(without reducing agents) for 5 min at room temperature, and loaded onto a protein gel for 
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Western blot analysis. HRP-conjugated anti-FLAG (Sigma M2) and anti-HA (Sigma) 
antibodies were used to probe for free and cross-linked arrestin and rhodopsin proteins.
Hydrogen-Deuterium Exchange Mass Spectrometry (HDX)
HDX was carried out as described previously80, with the following modifications: 1) the 
solution handling and mixing was performed with a LEAP Technologies Twin HTS PAL 
liquid handling robot housed inside a temperature-controlled cabinet held at 4 °C and 2) 
decyl maltose neopentyl glycol (DMNG) was used in place of DDM in the exchange buffer. 
Briefly, all stock solutions and dilutions were made using the 7TM HDX buffer (50 mM 
HEPES (pH 7.5), 150 mM NaCl, 2% (v/v) glycerol, 0.01% (m/v) CHS and 0.05% (m/v) 
DMNG in either H2O or in D2O for on-exchange). All HDX protein stock solutions were 
prepared at 15 μM in the 7TM HDX H2O buffer. On-exchange was carried out in triplicate 
for predetermined times (10, 30, 60, 900 and 3600 sec) at 4 °C by mixing 5 μL of stock 
protein solution with 20 μL of D2O on-exchange buffer. Exchange was quenched by adding 
25 μL of quench solution (100 mM NaH2PO4, 0.02% DMNG, and 15 mM TCEP at pH 2.4) 
to the reaction. Digestion was performed in line with chromatography using an in-house 
packed pepsin column. Peptides were captured and desalted on a C8 trap. Peptides were then 
separated across a 5 μ 10×1 mm Betasil C8 column (Thermo Fisher Scientific) with a linear 
gradient of 12–40% acetonitrile in 0.3% formic acid over a short 5 min gradient to limit 
back exchange with the solvent.
Mass spectra were acquired in the range of m/z 300–2000 at a resolution of 60,000 for 8 min 
in positive ion mode on a Q Exactive mass spectrometer (Thermo Fisher Scientific) 
equipped with an ESI source operated at a capillary temperature of 225 °C and spray voltage 
of 3.5 kV. The intensity weighted average m/z value (centroid) of each peptide’s isotopic 
envelope was calculated with the Workbench program81 and converted to % deuterium 
values. Back-exchange correction was based on an estimated 70% deuterium recovery and 
accounting for the known 80% deuterium content of the on-exchange buffer. The 
Workbench software used P-values lower than 0.05 for two consecutive time points to 
determine significance. Sequence coverage experiments for these proteins were carried out 
in the 7TM HDX buffer and LC system described above, but with a longer 60 min gradient. 
75 pmol of protein were loaded onto the column. For sequencing, tandem mass spectra were 
obtained using data-dependent acquisition with 30 second dynamic exclusion, where the top 
five most abundant ions in each scan were selected and subjected to CID fragmentation. 
Each scan was the average of 3 microscans under normal scan mode in both MS and 
MS/MS. Peptides were identified by searching spectra against an in-house database using 
the mascot search engine as described previously45.
Generation of a stable cell line expressing bovine rhodopsin mutant Y74C/C140S/C316S 
and rhodopsin preparation
The rhodopsin mutant Y74C/C140S/C316S gene82 was PCR-amplified from the pMT vector 
by using two flanking primers containing NheI and NotI restriction sites and subcloned into 
vector PB-T-PAF83. The insert in the resulting plasmid termed PB-Rho-Y74C was verified 
by automated DNA sequencing.
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HEK293S GnTI− cells84 were cultured in DMEM/F12 (Wisent) supplemented with 10% 
heat inactivated FBS (Life Technologies) and 100 U/ml penicillin/streptomycin (Life 
Technologies) and incubated at 37 °C, 5% CO2. For transfection, cells were plated in 6-well 
plates at a density of ~600,000 cells per well. The following day, cells were co-transfected 
with 4 μg of PB-Rho-Y74C, 0.5 μg of PB-RB83 and 0.5 μg of pCyL4383,85 using JetPrime 
(PolyPlus) reagent following the manufacturer’s instructions and medium was replaced by 
fresh medium 4 hours later. (Plasmids PB-T-PAF and PB-RB were provided by James Rini, 
University of Toronto, Canada, and pCyL43 by the Wellcome Trust Sanger Institute, UK). 
Two days after transfection, cells were transferred to a 100-mm tissue culture plate. Dual 
drug selection was started the following day, using 10 μg/ml puromycin (Bioshop) and 5 
μg/ml blasticidin (Bioshop) and lasted for 2 week. Cells were then transferred to larger 
flasks and finally to pleated roller bottles (Thermo Scientific) containing 250 ml of 
DMEM/F12 supplemented with 10% heat inactivated FBS and 100 U/ml of penicillin and 
streptomycin. Roller bottles were incubated at 37 °C, 5% CO2 and rotated at 0.1 rpm. 
Expression was induced after 5–6 days by replacing medium with 250 ml of fresh medium 
containing 1 μg/ml doxycycline (Bio Basic) and 1 μg/ml aprotinin (Bioshop). On day 3 after 
induction, cells were harvested, using PBS-EDTA with protease inhibitor tablet (Roche) to 
detach cells. Cell pellets were flash frozen in liquid nitrogen and stored at −80°C until 
purification.
For purification, cell pellets with rhodopsin mutant Y74C/C140S/C316S were incubated 
with 11-cis retinal to reconstitute rhodopsin which was purified and spin labeled with 1-
oxyl-2,2,5,5-tetramethyl-3-pyrroline-3-methyl methanethiosulfonate (MTSSL) as previously 
described41.
Incorporation of Spin Labeled Rhodopsin into Nanodiscs
Nanodiscs were prepared by mixing cholate solubilized lipid (70% POPC + 30% POPS), 
scaffolding protein MSP1E3D186, and rhodopsin (in 90 mM β-OG) in a molar ratio of 
140:1:0.1. The OG and cholate were removed from the mixture by dialysis against buffer D 
(20 mM MOPS, 150 mM NaCl, pH 6.8). The nanodiscs were further purified by passing 
them over a nickel NTA column to remove any receptor not incorporated into the discs. 
Upon elution from the nickel column with imidazole, the nanodiscs were buffer exchanged 
into buffer D containing 10% glycerol.
Spin Labeling of Arrestin Mutants
C-terminally truncated mutants of arrestin, lacking endogenous cysteines, have been shown 
to bind to non-phosphorylated rhodopsin87. Single-cysteine mutants in this background were 
expressed in E. coli, as described88, spin labeled in buffer D overnight using a 10-fold molar 
excess of MTSSL. The base mutant also contained two alanine substitutions (F85A and 
F197A) which have been shown to disrupt arrestin-1 oligomerization88. Non-covalently 
bound spin label was removed from the sample by extensive washes with buffer D using 
Amicon 10 kDa concentrators.
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DEER Spectroscopy of the rhodopsin-arrestin fusion complex
Preparations of rhodopsin (Y742.41C) and bovine arrestin (S60C, V139C, and L240C, which 
correspond to the mouse arrestin T61C, V140C, and T241C) and their spin labelling were 
performed as described previously41. For DEER measurements, the spin-labeled proteins 
were mixed in 1:1 ratio in the dark and loaded into quartz capillaries (1.5 mm ID and 1.8 
mm OD). The samples were irradiated for 30 sec within the capillaries using a tungsten light 
source with a 500 nm cutoff filter. Immediately after irradiation, the samples were flash 
frozen in liquid nitrogen, and loaded into an EN 5107D2 resonator for Q band DEER 
measurements. Measurements were performed at 80K on a Bruker Elexsys 580 spectrometer 
with a Super Q-FTu Bridge. A 36-ns π-pump pulse was applied to the low field peak of the 
nitroxide field swept spectrum, and the observer π/2 (16 ns) and π (32 ns) pulses were 
positioned 50 MHz (17.8 G) upfield, which corresponds to the nitroxide center line. Model-
free distance distributions were obtained from the raw dipolar evolution data using the 
LabVIEW (National Instruments) program “LongDistances” that can be downloaded from 
http://www.biochemistry.ucla.edu/biochem/Faculty/Hubbell/.
To estimate the median distances, the distance distributions were integrated and normalized 
to the maximum amplitude. The median distance was estimated as that corresponding to 0.5 
of the integrated intensity. The modeled distances between nitroxide spinlabels are based on 
the crystal structure of the rhodopsin-arrestin complex. R1 nitroxide sidechains were 
modeled into the structure using common R1 rotamers89,90.
9.7 MAG/Water Temperature-Composition Phase Diagram
The phase diagram was constructed based on small- and wide-angle X-ray scattering 
measurements made in the heating direction. Sample preparation and X-ray scattering 
measurements and analysis were as previously described55,91. The phases identified include 
the lamellar crystalline (Lc) or solid phase, the fluid isotropic (FI) or liquid phase, and the 
following liquid crystalline phases: lamellar liquid crystal (Lα), cubic-Ia3d and cubic-Pn3m. 
A separate aqueous phase observed in equilibrium with the solid or liquid crystalline phases 
is indicated by Aq. The phase diagram shows that the solid Lc phase stabilizes under 
equilibrium conditions below ~8 °C. The latter is some 10 °C below that observed with 9.9 
MAG (monoolein)91 and is similar to what was found with 7.9 MAG92. This low 
solidification temperature enabled use in the current project of 9.7 MAG as a host lipid for 
LCP-SFX data collection in an evacuated sample chamber at 20 °C, where evaporative 
cooling created problems for measurements with 9.9 MAG but not with 7.9 MAG35. The 
maximum water carrying capacity of 9.7 MAG resides at ~50 %(w/w) water, which is 
considerably greater and smaller than that of 9.9 MAG91 and 7.7 MAG93, respectively. 
These observations indicate that the cubic mesophase of 9.7 MAG has larger aqueous 
channels compared to 9.9 MAG that are more like those of 7.7 MAG. This is consistent with 
9.7 MAG supporting the growth of rhodopsin-arrestin-T4L crystals where the complex has 
sizable extra-membrane bulk best accommodated in a large aqueous channel. This parallels 
the observations made with 7.7 MAG as a host lipid for the β2AR-Gs complex structure 
determination8.
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Molecular Modeling of the Full Length Rhodopsin-Arrestin Complex
Energy-based conformational modeling of the rhodopsin-arrestin complex was performed 
with the ICM-Pro molecular suite 94, using a global energy optimization procedure similar 
to the one described recently for modeling of the full-length complex of CRFR195. Protein 
sequences of human rhodopsin and mouse arrestin were obtained from the Uniprot database 
(http://www.uniprot.org/). Starting from the crystallographically determined structure of the 
complex, the modeling procedure was used to add unresolved residues of the C-terminus 
(residues 327–345) of the human rhodopsin structure, as well as missing residues in the 
arrestin loop (residues 340–342) of the mouse arrestin structure. The final model did not 
include the last 3 residues of rhodopsin (346–348), which lack well defined crosslinking 
contacts and appear flexible. Initial conformations of the short loop in arrestin were 
predicted with the fast “build model” ICM algorithm, followed by extensive energy 
optimization in internal coordinates. Conformational optimization of the rhodopsin C-
terminal peptide was guided by soft pairwise harmonic distance restraints derived from 
disulfide crosslinking data. The restraints introduced between Cβ atoms of the crosslinked 
residues were graded according to the crosslinking strength listed in Supplementary Table 5, 
from very strong, with the penalty function starting at 5 Å distance, to medium at 7 Å 
distance and very weak at 12 Å. The C-terminal peptide conformation and conformation of 
the contact side chains of the arrestin were optimized to convergence (3 independent 
simulations of 106 steps) using global optimization procedure in internal coordinates with 
improved conformational energy terms for protein and peptides 96. A special backbone 
closure sampling procedure was applied to the loop regions to allow efficient optimization. 
The global optimization runs were executed in parallel on a Linux multicore server resulting 
in similar best energy conformations (<3 Å RMSD; root mean squared deviation) for the C-
terminal peptide residues.
The best energy-optimized conformation of this region suggests that the extended C-
terminus peptide runs antiparallel along the N-terminal β-strand of arrestin. This 
conformation of the C-terminus satisfied all 17 medium to strong disulfide crosslinking 
restraints for this region (Supplementary Table 5), while making a number of specific polar 
interactions and salt bridges of D331, E332 and E341side chains with arrestin basic residues 
(Extended Data Figure 5). These modeling results suggest that though the rhodopsin C-
terminus is rather flexible, some low energy conformations may be preferable even in non-
phosphorylated rhodopsin. Moreover, independent modeling of the complex with 
phosphorylated serine residues Ser334, Ser338 and Ser343 in the C-terminus of rhodopsin 
resulted in a similar conformation of this domain. The interactions within phosphorylated 
complex, however, are greatly enhanced by as many as seven additional salt bridges 
between negatively charged phosphates and the positively charged lysine and arginine 
residues within the N- terminal domain of arrestin (Extended Data Figure 11).
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Extended Data
Extended Data Fig. 1. Constitutively active rhodopsin interacts with arrestin and GαCT
a. SDS-PAGE of N-terminally MBP-tagged WT and mutant rhodopsin.
b. Non-cropped versions of the pull-down assay gels shown in Fig. 1B. The interactions 
between mouse WT arrestin and human WT or E1133.28Q rhodopsin are very weak. In 
contrast, the interaction between constitutively active rhodopsin (E1133.28Q /M2576.40Y) 
and pre-activated L374A/V375A/F376A arrestin (3A_arrestin) is strong and is further 
increased in the presence of 10 μM all-trans retinal. Input: 5% of the binding reaction. 
Bottom panels show the rhodopsin loading controls.
c, Schematic representation of the AlphaScreen assay.
d. AlphaScreen binding assay between E1133.28Q /M2576.40Y rhodopsin and GαCT 
(TGGRVLEDLKSCGLF) in the presence and absence of 5 μM all-trans retinal. The two left 
columns show the controls with “peptide only” and “rhodopsin only”. (n=3, error bars=SD).
e. Determination of the affinity of the interaction between rhodopsin E1133.28Q /M2576.40Y 
and GαCT by homologous competition. His6 -MBP-rhodopsin mutant protein was 
immobilized on Ni-acceptor beads and biotinylated GαCT on streptavidin donor beads. 
Binding between rhodopsin and arrestin brings donor and acceptor beads into close 
proximity, resulting in the indicated binding signal. Non-biotinylated GαCT competed for 
the interaction with an IC50 of ~700 nM (n=3, error bars=SD).
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Extended Data Fig. 2. Purification and crystallization of T4L-rhodopsin-arrestin
a, Purification of the T4L-rhodopsin-arrestin (T4L-Rho-Arr) complex. His8-MBP-MBP-
T4L-Rho-Arr complex was first purified by amylose column chromatography (lane1). The 
His8-MBP-MBP tandem tag was then released by cleavage with 3C protease (lane 2) and 
removed by binding to Ni-NTA beads to recover pure T4L-rhodopsin-arrestin (T4L-Rho-
Arr) protein (lane 3).
b, Analytical gel filtration profile of the T4L-rhodopsin-arrestin complex. T4L-rhodopsin-
arrestin eluted mostly as monomers with a small proportion of oligomers. The molecular 
weights of protein standards are indicated at the top.
c, Thermal stability shift analysis of T4L-rhodopsin-arrestin. T4L-rhodopsin-arrestin is 
relatively stable with a Tm of 59 °C.
d, Crystals of T4L-rhodopsin-arrestin in lipidic cubic phase under bright field illumination 
(top) and polarized light (bottom).
e, X-ray diffraction pattern of a T4L-rhodopsin-arrestin crystal recorded at LS-CAT of APS. 
The green ring indicates the position of reflections at 8.0 Å resolution.
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Extended Data Fig. 3. Electron density map for the overall complex and the key interfaces based 
on the XFEL data
a, A 2Fo–Fc electron density map contoured at 1 σ of the arrestin finger loop, which forms 
the key interface with TM7 and Helix 8.
b, A 2Fo-Fc electron density map contoured at 1 σ of the loop between TM5 and TM6, 
which forms the key interface with the β-strand following the finger loop.
c, A 3000K simulated annealing omit map (2Fo-Fc electron density map contoured at 1 σ) 
calculated from the 3.8Å/3.8Å/ 3.3Å XFEL data supports the overall arrangement of the 
rhodopsin-arrestin complex. In all panels, the complex structure is shown with rhodopsin 
colored in green, arrestin in brown and T4L in yellow.
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f, Stereo views of the lariat loop with a 2Fo-Fc composite omit map at 1 σ calculated from 
the 3.8Å/3.8Å/ 3.3Å truncated XFEL data. Key residues are labeled.
Extended Data Fig. 4. Structure similarity of the four rhodopsin-arrestin complexes in the 
asymmetric units and the interface between rhodopsin and arrestin
a, Two 90° views of the superposition of the four rhodopsin-arrestin complexes are shown 
as cartoon representation. The four complexes have an RMSD of less than 0.5 Å in the Cα 
atoms of rhodopsin and arrestin.
b, Close-up view of arrestin-binding sites in rhodopsin. The four arrestin-binding sites (P1–
P4) are highlighted in brown on the rhodopsin surface. The rhodopsin C-terminal tail/
arrestin interface (P4) is based on computational modeling and disulfide crosslinking data.
c, Rhodopsin-binding sites in arrestin. The four rhodopsin-binding sites (P1-P4) are 
highlighted in green on the arrestin surface.
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Extended Data Fig. 5. Conformational modeling of the rhodopsin-arrestin full length complex
a, An overview of the computational model.
b, Predicted interactions of the rhodopsin C-terminus with arrestin, showing strong to 
medium pairwise restraints between Cβ atoms of rhodopsin and arrestin residues identified 
by disulfide crosslinking.
c, same as in b, but showing predicted hydrogen bonding and ionic interactions for the C-
terminal residues of rhodopsin.
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Extended Data Fig. 6. Dynamics of free 3A_arrestin and rhodopsin-bound arrestin determined 
by HDX
a, HDX perturbation map between rhodopsin-bound arrestin and free arrestin, which is 
derived from the difference in the HDX rate between rhodopsin-bound arrestin and free 
arrestin. The bars below the arrestin sequence represent the peptide fragments resolved by 
mass spectrometry and the colors of the bars indicate the relative decrease in deuterium 
exchange (color code at bottom).
b, The thermal stability of free 3A_arrestin and the rhodopsin-arrestin complex shows that 
the rhodopsin-arrestin complex is more stable than free 3A_arrestin.
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Extended Data Fig. 7. Cell based Tango assays to validate the rhodopsin-arrestin interface
a, Cartoon illustration of the Tango assay for rhodopsin-arrestin interactions in cells.
b–c, Mutations of key arrestin (b) and rhodopsin (c) residues that mediate the rhodopsin-
arrestin interactions. Tango assay were performed in the absence or presence of 10 μM all-
trans-retinal (ATR). (n=3, error bars=SD).
Kang et al. Page 25
Nature. Author manuscript; available in PMC 2016 January 30.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Extended Data Fig. 8. Control experiments for disulfide bond cross-linking specificity
a, The product of the cross-linking reaction of finger loop residue G77C with N3107.57C of 
TM7 was confirmed by western blots using anti-FLAG antibody (which detects arrestin-
FLAG fusion) and anti-HA antibody (which detects rhodopsin-HA fusion). The cross-linked 
products are marked with arrow heads, and free-arrestin and free-rhodopsin are indicated by 
asterisks. Arrestin (3A) and rhodopsin (4M) without cysteine mutations do not form cross-
linked products.
b, The cross-linked product of finger loop residue G77C with N3107.57C of TM7 was 
sensitive to treatment with reducing agents, indicating the cross-linking is mediated through 
disulfide bond formation.
c, A close-up view of arrestin finger loop residues M76C and G77C and their cross-linking 
with rhodopsin, which shows that G77C was specifically cross-linked to N3107.57C of TM7 
and Q3128.49 of Helix 8, and M76C was cross-linked to N3107.57C of TM7 and Q3128.49C 
of Helix 8, but not to other residues.
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d, Structure and cross-linking of finger loop N-terminal residues Q70C, E71C, and D72C of 
arrestin to T70C and K67C from ICL1 of rhodopsin.
e, Structure and cross-linking of arrestin back loop residues R319C and T320C to 
Q237ICL3C from TM5 of rhodopsin.
Extended Data Fig. 9. Structure comparison of the arrestin-bound rhodopsin with the β2-
adrenergic receptor in complex with Gs protein (PDB code: 3SN6) and the inactive rhodopsin 
(PDB code: 1F88)
a, Superposition of arrestin-bound rhodopsin (green) with Gs protein-bound β2 adrenergic 
receptor (light yellow). The major conformational changes are indicated by arrows.
b, An intracellular view of a superposition of arrestin-bound rhodopsin (green) and Gs 
protein-bound β2-adrenergic receptor (light yellow).
c, Overlays of arrestin-bound rhodopsin (green) with inactive rhodopsin (pink) reveals 
specific conformational changes in each TM helix. The arrows indicate outward movements 
of TM helices.
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d, RMSD of Cα atom differences between arrestin-bound rhodopsin and inactive rhodopsin 
shows the large conformational changes in TM5 and TM6.
Extended Data Fig. 10. Structure of rhodopsin-bound arrestin and its comparison with inactive 
and “pre-activated” arrestin
a–b, The charge potential surface map of rhodopsin from the rhodopsin-arrestin bound 
complex shows that the cytoplasmic rhodopsin TM bundle surface is positively charged 
(blue) whereas its C-terminal tail is negatively charged (red).
c–d, Charged surface of arrestin from the rhodopsin-arrestin bound complex shows that the 
arrestin finger loop is negatively charged (red) and its N-terminal β-strand interface is 
positively charged (blue). The charge distribution in rhodopsin and arrestin is 
complementary to each other for their interactions.
e, Comparison of rhodopsin-bound arrestin (light blue) with inactive arrestin (brown, PDB 
code: 1CF1), showing an ~20° rotation between the N- and C- domains of arrestin.
f, Comparison of rhodopsin-bound arrestin (dark brown) with pre-activated arrestin (light 
brown, PDB code: 4J2Q), showing conformational changes in the finger loop, which adopts 
an α-helical conformation (cyan) in the complex. The extended finger loop conformation 
would protrude into the rhodopsin TM bundle and is not compatible with receptor binding.
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Computational model for the full rhodopsin-arrestin complex is shown in panels (b) and (d).
Extended Data Fig. 11. A computational model of phosphorylated rhodopsin in complex with 
arrestin and salt sensitivity of the rhodopsin-arrestin interaction
a–d, An overall view (a) and close-up views (b–d) of the computational model of the 
rhodopsin C-tail with phospho-serine at positions 334, 338 and 343 in complex with arrestin.
e, The AlphaScreen control (biotin-His6) shows much less salt sensitivity than the 
interaction between His-tag-rhodopsin and biotin arrestin, which is very sensitive to salt, 
with an IC50 of around 200 mM NaCl (100 mM NaCl added to 100 mM salt of the original 
assay buffer) (n=3, error bars=SD).
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Extended Data Fig. 12. A positive charge property is commonly found at the cytoplasmic side of 
GPCRs
a–e, Surface charge potential of the cytoplasmic side of selected agonist bound GPCR 
structures: β1AR, PDB code: 2Y02 (a); β2AR, PDB code: 3PDS (b); A2A adenosine 
receptor, PDB code: 3QAK (c); serotonin receptor 5HT1B, PDB code: 4IAR (d); serotonin 
receptor 5HT2B, PDB code: 4IB4 (e). Positive and negative charge potentials are shown in 
blue and red, respectively.
f, Sequence alignment of the finger loop region highlighting negatively charged residues 
(shown in red), which are conserved in all subtypes of arrestins.
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Extended Data Fig. 13. A possible role of the arrestin C-edge in lipid binding
a,b The asymmetric assembly of the rhodopsin-arrestin complex in the presence of a lipid 
membrane bilayer, showing the C-edge of arrestin dipping into the lipid layer.
c,d, A close-up view of the C-edge of arrestin in the membrane layer, where the conserved 
hydrophobic side chains are shown. The figure was made using the computational model for 
the full rhodopsin-arrestin complex.
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Figure 1. Rhodopsin-arrestin interactions and complex assembly
a, Diagram of the binding of rhodopsin (Rho) with G-protein and arrestin as described in the 
main text. Labels are 11-cis retinal (ECR) and all-trans-retinal (ATR).
b, Rhodopsin and arrestin interaction determined by pull-down assay in the absence and 
presence of ATR (top panel). Middle panel: rhodopsin loading controls. Bottom panel: 
Relative binding of 35S-labelled arrestin was determined by densitometry (n=3, error 
bars=SD).
c, Binding of His8-MBP-rhodopsin (E1133.28Q /M2576.40Y) protein to biotin-MBP-arrestin 
(WT and 3A) measured by AlphaScreen in the absence or presence of 5 μM ATR. The first 
six columns are controls (luminescence signals in the presence of only one of the binding 
partners; n=3, error bars=SD).
d, Competition of arrestin binding to rhodopsin was determined by a homologous 
AlphaScreen assay and the IC50 value was derived from repeat experiments (n=3, error 
bars=SD).
e, Negative stain EM images of rhodopsin-arrestin complexes without or with T4L at the N-
terminus; Right panel: Overlay of the EM image with the structures of T4L, rhodopsin and 
arrestin. m: detergent micelle.
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Figure 2. The structure of the rhodopsin-arrestin complex
a, The structure of the rhodopsin-arrestin complex in four orientations. The relative 
dimensions of rhodopsin and arrestin are shown in the intracellular view. TM1-TM7 
indicates rhodopsin transmembrane helices 1–7; H8 is intracellular Helix 8.
b, An overall view of the rhodopsin-arrestin complex shown with transparent solid surface. 
T4 Lysozyme (T4L) is omitted from this view.
c, Crystal packing diagram of the rhodopsin-arrestin complex with T4L as yellow ribbon 
model.
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Figure 3. DEER validation of rhodopsin-arrestin complex assembly
a, An overall view of rhodopsin-arrestin assembly showing the three intermolecular 
distances based on the models of the R1 nitroxide pairs at rhodopsin residue Y742.41 and 
three arrestin residues T61, V140, and S241 based on the crystal structure.
b–d, The experimental distance distributions between the nitroxide spin labeled R1 pairs of 
rhodopsin Y742.41 and bovine arrestin S60, V139, and L240, which are in equivalent 
positions to mouse arrestin T61(b), V140 (c), and S241(d) as labeled in the figure. Y axes 
are the probability of distance distribution.
Kang et al. Page 41
Nature. Author manuscript; available in PMC 2016 January 30.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 4. The rhodopsin-arrestin interface and its validation by HDX
a–b, Two overall views showing the four interface patches of the rhodopsin-arrestin 
complex.
c–d, Mapping of HDX on the rhodopsin-bound arrestin structure. Rhodopsin is colored in 
red and arrestin is colored based on the exchange rate differences between free 3A_arrestin 
and rhodopsin-bound arrestin as shown in Extended Data Fig. 6a. This figure was made 
using a computational model of the full rhodopsin-arrestin complex.
Kang et al. Page 42
Nature. Author manuscript; available in PMC 2016 January 30.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 5. Validation of the rhodopsin-arrestin interface by disulfide bond cross-linking
a–e, Structure and cross-linking of arrestin with rhodopsin. Panels are arrestin finger loop 
with rhodopsin TM7 and helix 8 (a); arrestin middle loop with rhodopsin ICL1 (b); arrestin 
lariat loop residue Y251 with rhodopsin TM5 (c); arrestin β-strand interface residues with 
residues of rhodopsin TM5, ICL3, and TM6 (d); and arrestin’s N-terminus with rhodopsin’s 
C-tail (e). Rhodopsin K311 is marked with a red star and arrestin M76 is show in full for 
clarity. Part of the computational model for the full rhodopsin-arrestin complex was used in 
panel (e).
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Figure 6. Structural basis of arrestin-biased signaling and arrestin recruitment
a–b, Two views of structural overlays of arrestin-bound rhodopsin (green) with inactive 
rhodopsin (pink).
c–d, Two views of structural overlays of arrestin-bound rhodopsin (green) with GαCT 
peptide-bound rhodopsin (orange).
e, A cartoon model of arrestin recruitment by a phosphorylated and active rhodopsin. In the 
dark state, the receptor is inactive (R-state) and arrestin is in the closed state (basal state). 
Receptor activation and phosphorylation (P-R* state) allow the phosphorylated C-terminal 
tail of rhodopsin to bind to the N-domain of arrestin (pre-activated state), thus displacing the 
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arrestin C-terminal tail. This displacement destabilizes the polar core of arrestin, which 
allows a 20° rotation between the arrestin N- and C- domains, leading to the opening of the 
middle loop (ML) and lariat loop (LL) to accommodate the ICL2 helix of rhodopsin (fully-
activated state). The activated receptor also opens the cytoplasmic side of the TM bundle to 
adopt the finger loop (FL) of arrestin.
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